Dyve Biosciences
Renee Arakawa has over 25 years of industry experience and more than 15 years managing and directing clinical trials and overseeing operational teams in a CRO environment. She has led global and regional trials, phases I through IV, and has vast industry experience, including the university environment and over 10 years at PPD, one of the world leaders in serving science. Renee brings a wide breadth of therapeutic experience, including small, specialized studies, pediatric, and rare disease studies. She earned a Master of Science in Human Cancer Biology from the University of Wisconsin-Madison, as well as a BA with distinction in both Biology and History as a double major from Occidental College.
This person is not in any offices
Dyve Biosciences
1 followers
Dyve is a clinical-stage biotech company with its lead asset, DYV700, currently completing a 20-center, 100-patient, Phase 2 clinical study for the treatment of acute gout.